C. Barrie

Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial.

K. Brock, Y. Summers, G. Middleton, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Characterisation and outcomes of patients referred to a regional cancer of unknown primary team: a 10-year analysis

M. Stares, S. Clive, K. Purshouse, 2021, British Journal of Cancer.

A biobank analysis of prognostic biomarkers of the systemic inflammatory response in patients presenting with malignancy of undefined primary origin.

M. Stares, B. Laird, D. McMillan, 2020, European journal of cancer.

Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial.

L. Billingham, K. Brock, S. Lee, 2020, The Lancet. Respiratory medicine.

Hypoalbuminaemia as a Prognostic Biomarker of First-Line Treatment Resistance in Metastatic Non-small Cell Lung Cancer

M. Stares, J. Leach, I. Phillips, 2021, Frontiers in Nutrition.

Real-World Impact of SABR on Stage I Non-Small-Cell Lung Cancer Outcomes at a Scottish Cancer Centre

M. Stares, I. Phillips, M. Mackean, 2023, Cancers.

Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer

M. Stares, K. Cumming, I. Phillips, 2022, ESMO open.

Early prehabilitation in suspected locally advanced and metastatic lung cancer

N. Macdonald, I. Phillips, M. Mackean, 2023, BMJ supportive & palliative care.

Challenging Presentations of Germ Cell Tumours in Routine Clinical Practice

Jeff White, N. Bezawada, A. Waterston, 2021, The journal of the Royal College of Physicians of Edinburgh.

Immune-Related Adverse Events, Biomarkers of Systemic Inflammation, and Survival Outcomes in Patients Receiving Pembrolizumab for Non-Small-Cell Lung Cancer

M. Stares, M. Mackean, C. Barrie, 2023, Cancers.